** Brokerage BofA Global Research cuts PT on drugmaker Pfizer PFE.N to $26 from $29 ahead of Q1 results on April 29
** Maintains "neutral" rating on the stock
** The new price target represents a 17.4% upside to the stock's last close
** "Major focus expected to be on potential tariff impact, drug pricing, RFK Jr and vaccine risk, and key brand competition" - BofA
** The brokerage firm expects Q1 total revenue to drop by 2% due to changes in Medicare prescription drug program known as Part D assumptions and antiviral treatment Paxlovid seasonality
** BofA analysts believe PFE's long-term growth prospects are below average due to upcoming patent expiries and competitive threats
** Eight of 22 brokerages rate the stock "buy" or higher, 14 "hold"; their median PT is $29.5 - LSEG data
** Up to last close, PFE has fallen 17%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.